Elephas key facts
as of Oct 2026- Operator of a live tumor imaging diagnostics company intended to determine the cancer therapy for each patient.
- Elephas is valued at approximately $281.0M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $167.2M across 4 recorded rounds; the latest was Later Stage VC ($51.2M) in Nov 2023.
- Notable investors include ARCH Venture Partners, Moore Strategic Ventures, Sands Capital, Tao Capital Partners, WARF Ventures — 9 tracked in total.
- Elephas has filed 4 Form Ds with the SEC since 2021, most recently Jan 2024 ($51.2M sold to 10 investors).
- Status: Privately Held (backing).
Valued at $281.0M at its later-stage round, Nov 2025. Nothing has traded since.
- ·Watch Elephas: the Monday email on marks, rounds and moves
Elephas funding rounds
4 roundsElephas leadership
- Carolyn MorganExecutive
- Hinco GiermanChief Scientific Officer
- Premal PatelChief Medical Officer
- Terry BradyChief Financial Officer
Elephas valuation
Elephas was valued at $281 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Elephas raised?
Elephas has raised $167 million across 4 recorded rounds since 2021. The largest was a $51.2 million later-stage round in Nov 2023.
Elephas has filed 4 Form Ds with the SEC since 2021, most recently in Jan 2024 ($51.2 million sold to 10 investors).
Elephas investors
9 investors are on record for Elephas, including ARCH Venture Partners, Moore Strategic Ventures, Sands Capital and Tao Capital Partners. By type, the record holds 4 venture capital firms, 1 hedge fund and 1 growth equity firm. The later-stage round in Nov 2023 drew 10 investors.
Who runs Elephas
11 people are listed on the Elephas team: 5 executives and 6 board members, including Terry Brady (Chief Financial Officer) and Carolyn Morgan (Executive). 11 of them have a verified direct contact on file.
About Elephas
Operator of a live tumor imaging diagnostics company intended to determine the cancer therapy for each patient. The company's platform harnesses the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, and focuses on human live tumor fragments, enabling clinicians to treat cancer patients and accelerate drug development.
- Sector
- Healthcare
- HQ
- Madison, WI, United States
- Founded
- 2020
- Employees
- 100
- Website
- elephas.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.